Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2015

View Archived Issues

ATRX gene mutations identified as a potential biomarker for clinically aggressive PCC/PGL

Ono Pharmaceutical updates progress of third quarter of fiscal 2014

Shionogi reports milestones of third quarter of fiscal 2014

Isis Pharmaceuticals reports data from phase II study of ISIS-PTP1B Rx in type 2 diabetes

Belsomra now available in the U.S. to treat insomnia

InMed begins program targeting Epidermolysis bullosa simplex

ACEA Biosciences patents BTK inhibitors

CytoDyn concludes phase II PRO-140 trial and submits phase III protocol to FDA

Leading BioSciences cleared to begin phase II study of LB-1148 in septic shock

Regulus earns milestone payment under Biogen Idec research collaboration

Launch of new biotech start-up OptiKira

Diamyd Medical starts pilot trial of type 1 diabetes vaccine injected into lymph nodes

BioLight updates development progress of tests for bladder cancer and dry eye

Wound care specialist AlliquaBioMedical agrees to acquire device developer Celleration

NIHR and Janssen to study rheumatoid arthritis response to anti-TNF therapy

Polaris initiates phase I trial of ADI-PEG20 plus FOLFOX in gastrointestinal cancers

U.S. researchers prepare new deuterated droxidopa derivatives

Amgen releases topline results from phase III study of adalimumab biosimilar ABP-501

Scientists at BMS disclose XIAP inhibitors

New AXL kinase inhibitors patented by Ono Pharmaceuticals

Cynata's mesenchymal stem cells to be tested in animal model of lung fibrosis

Obinutuzumab extends PFS in phase III indolent non-Hodgkin's lymphoma trial

FDA accepts for review CSL Behring's BLA for rIX-FP

New data presented for an inhibitor of tau aggregation in Alzheimer's disease treatment

rEVO Biologics funds pre-eclampsia research center at Yale University

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...